Background <p>Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers and fundamental mechanisms.</p> Methods <p>Patients with NSCLC and BrM planning to receive ICI therapy were enrolled in the…
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases
Journal for ImmunoTherapy of Cancer | | Li, Y.-S., Lai, W., Yin, K., Tu, H.-Y., Li, L., Lin, S.-H., Li, P., Zhou, D.-X., Guo, W.-B., Yang, J.-J., Zhou, Q., Zhong, W.-Z., Zhang, X.-C., Jiang, B.-Y., Wang, Z., Yang, X.-N., Wang, B.-C., Pan, Y., Chen, H.-J., Xu, C.-R., Zeng, L., Chen, Z.-H., Yan, H.-H., Sun, H., Dong, Z.-Y., Liu, S.-Y. M., Li, Y., Luo, O. J., Zheng, M.-M., Wu, Y.-L.
Topics: lung-cancer, blood-cancer, brain-cancer, immunotherapy, targeted-therapy, research
Read the full article at Journal for ImmunoTherapy of Cancer